MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
February 01 2022 - 2:00AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider
of enabling platform technologies for ex-vivo cell engineering,
today announces the signing of a strategic platform license (SPL)
with Intima Bioscience, Inc., a clinical stage biotechnology
company developing genetically engineered cell therapies for solid
tumor cancer. Intima joins a group of 15 other leading cell therapy
companies who have partnered with MaxCyte.
Under the terms of the agreement, Intima obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
Intima is currently running a Phase 1/2 clinical
study (NCT04426669) of its lead checkpoint cell therapy candidate,
which targets the immune checkpoint CISH in patients with
gastrointestinal and colon cancers.
“As we advance our innovative eTIL CISH knock out programs, we
are preparing for the future by securing access to MaxCyte’s
industry leading cellular engineering technology,” said
Alessandro Riva, M.D., Intima CEO.
Doug Doerfler, President and CEO of
MaxCyte, said: “We are proud to be working with Intima, a
cell therapy leader leveraging the unique power of genetically
engineered tumor infiltrating lymphocytes (eTIL). This relationship
represents an important achievement for MaxCyte as it expands the
use of our next-generation technology platform to support
engineering in additional novel cell types.”
MaxCyte’s ExPERT™ instrument portfolio is the
next generation of leading, clinically-validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Intima Bioscience is MaxCyte’s 16th SPL,
which generate pre-commercial milestone revenue and the vast
majority of which include post-commercial revenue.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™ GTx™and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
About Intima Bioscience
Intima Bioscience is a company advancing
checkpoint cell therapy, an approach that combines the use of
patients’ own immune cells with immune checkpoint targeting, in
solid tumors with curative intent. Intima is currently running
a Phase 1/2 clinical study of its checkpoint cell
therapy, which targets the immune checkpoint CISH in patients with
gastrointestinal and colon cancers.
MaxCyte Contacts:
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1 415-937-5400
ir@maxcyte.com |
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024